Zimbabwe has rejected a major American health deal worth 367 million US dollars (£272m) over five years over Washington's request for confidential data.
The decision became public after a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government representative later explained that the US was demanding access to genetic material for research and commercial gain but was unwilling to share the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more negotiations to secure a deal acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Wider Implications
This rejection comes after a similar situation in neighbouring Kenya, where a court halted a related health funding agreement following concerns were raised about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government agreements to boost openness and accountability.
According to statements, 16 African countries have to date agreed to similar agreements, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that might result from that shared data," his statement read.
"Put simply, our country would provide the raw materials for medical research without any assurance that the final treatments would be available to our population should a future health crisis emerge."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its push of one-on-one deals were undermining structures previously established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This framework is designed to ensure that when a country contributes its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration might be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but recommended that negotiations must proceed since a large portion of the nation's Aids initiatives relied on international support.
"Where technical issues exist, such as those relating to information security or agreement terms, these can frequently be addressed via technical clarification and negotiated safeguards," it said.
The halted deal emphasises the complex debate between receiving vital foreign assistance and protecting a country's data in an increasingly data-driven world.